Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a descriptive, prospective, observational and epidemiological study on participants recently diagnosed with breast cancer to evaluate the HER2 status by IHC and SISH procedures.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Breast Cancer Participants | Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ Hybridization (SISH) Procedures | HER2 status of the collected tissue samples was determined based on the results obtained from IHC test and SISH procedure. The IHC test gives a score of 0 to 3 positive (+) that measures the amount of HER2 receptor protein on the surface of cells in a breast cancer tissue sample. If the score is 0 to 1+, it's called "HER2 negative (-)." If the score is 2+, it's called "borderline." A score of 3+ is called "HER2 positive." Tissue samples which had the IHC score of 2+ (borderline) were re-tested using SISH procedure for confirmation of the HER2 status. Tissue samples with SISH test results + were considered as HER2+. Tissue samples for which HER2 status was not determined were considered as HER2 equivocal. | Baseline up to 30 months |
| Percentage of Participants With Different Phenotypes of Breast Cancer | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were estrogen receptor (ER) + and/or progesterone receptor (PR) +, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. Histological grading was done by Nottingham Histologic Score system based on three factors, a) the amount of gland formation (differentiation), b) the nuclear features (pleomorphism) and c) the mitotic activity. Each of these features is scored from 1-3, and then each score is added to give a final total score ranging from 3-9. The final total score is used to determine the grade in the following way: i) Grade 1 tumors have a score of 3-5, ii) Grade 2 tumors have a score of 6-7, and iii) Grade 3 tumors have a score of 8-9. | Baseline up to 30 months |
| Percentage of Participants With Histological Sub-types of Breast Cancer | Histological subtypes of breast cancer included ductal carcinoma, lobular carcinoma, mucinous carcinoma, mixed carcinoma, metaplastic carcinoma, and others. |
Not provided
Not provided
Inclusion Criteria:
- Anatomopathological samples (surgical specimens or when a surgical sample is not possible, a core needle biopsy may be used) from female participants with a histopathological diagnosis of invasive breast cancer
Exclusion Criteria:
Not provided
Not provided
Not provided
Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies when surgery is not possible.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lima | LIMA 11 | Peru | ||||
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Breast Cancer (BC) Participants | Breast tissue samples from female participants with a breast cancer diagnosis that underwent an anatomopathological examination of surgical specimens and/or core needle biopsies were considered for analysis in this study. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
All participants were included.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Breast Cancer Participants | Breast tissue samples from female participants with a breast cancer diagnosis that underwent an anatomopathological examination of surgical specimens and/or core needle biopsies were considered for analysis in this study. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ Hybridization (SISH) Procedures | HER2 status of the collected tissue samples was determined based on the results obtained from IHC test and SISH procedure. The IHC test gives a score of 0 to 3 positive (+) that measures the amount of HER2 receptor protein on the surface of cells in a breast cancer tissue sample. If the score is 0 to 1+, it's called "HER2 negative (-)." If the score is 2+, it's called "borderline." A score of 3+ is called "HER2 positive." Tissue samples which had the IHC score of 2+ (borderline) were re-tested using SISH procedure for confirmation of the HER2 status. Tissue samples with SISH test results + were considered as HER2+. Tissue samples for which HER2 status was not determined were considered as HER2 equivocal. | Included breast cancer tissue samples from all participants who were willing to participate in the study. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
Not provided
Collection of adverse events data was not applicable as the present study was non-interventional and performed on breast cancer tissue samples obtained from breast cancer participants.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Breast Cancer Participants | Breast tissue samples from female participants with a breast cancer diagnosis that underwent an anatomopathological examination of surgical specimens and/or core needle biopsies were considered for analysis in this study. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Communications | Hoffmann-La Roche | 800-821-8590 | genentech@druginfo.com |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline up to 30 months |
| Percentage of Participants With ER Status (Positive or Negative) Across Different Age Groups | Participants were categorized in to following age groups: a) less than (<) 40 years, b) 40-49 years, c) 50-59 years, d) 60-69 years, e) greater than or equal to (≥) 70 years. | Baseline up to 30 months |
| Percentage of Participants With ER Status (Positive or Negative) Based on Nuclear Grades | Nuclear pleomorphism was observed and graded accordingly. Grade 1: Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size; Grade 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape; Grade 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms. | Baseline up to 30 months |
| Percentage of Participants With ER Status (Positive or Negative) Based on Lymphovascular Invasion | Lymphovascular invasion is entering of breast cancer cells in to the lymph or vascular/blood channels. | Baseline up to 30 months |
| Percentage of Participants With PR Status (Positive or Negative) Across Different Age Groups | Participants were categorized in to following age groups: a) <40 years, b) 40-49 years, c) 50-59 years, d) 60-69 years, e) ≥70 years. | Baseline up to 30 months |
| Percentage of Participants With PR Status (Positive or Negative) Based on Nuclear Grades | Nuclear pleomorphism was observed and graded accordingly. Grade 1: Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size; Grade 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape; Grade 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms. | Baseline up to 30 months |
| Percentage of Participants With PR Status (Positive or Negative) Based on Lymphovascular Invasion | Lymphovascular invasion is entering of breast cancer cells in to the lymph or vascular/blood channels. | Baseline up to 30 months |
| Percentage of Participants With HER2 Status (Positive or Negative) Across Different Age Groups | Participants were categorized in to following age groups: a) <40 years, b) 40-49 years, c) 50-59 years, d) 60-69 years, e) ≥70 years. | Baseline up to 30 months |
| Percentage of Participants With HER2 Status (Positive or Negative) Based on Nuclear Grades | Nuclear pleomorphism was observed and graded accordingly. Grade 1: Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size; Grade 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape; Grade 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms. | Baseline up to 30 months |
| Percentage of Participants With HER2 Status (Positive or Negative) Based on Lymphovascular Invasion | Lymphovascular invasion is entering of breast cancer cells in to the lymph or blood/vascular channels. | Baseline up to 30 months |
| Percentage of Participants With Different Phenotypes of Breast Cancer Across Different Age Groups | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. Participants were categorized in to following age groups: a) <40 years, b) 40-49 years, c) 50-59 years, d) 60-69 years, e) ≥70 years. | Baseline up to 30 months |
| Percentage of Participants With Different Phenotypes of Breast Cancer Based on Nuclear Grades | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. Nuclear pleomorphism was observed and graded accordingly. Grade 1: Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size; Grade 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape; Grade 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms. | Baseline up to 30 months |
| Percentage of Participants With Different Phenotypes of Breast Cancer Based on Lymphovascular Invasion | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. Lymphovascular invasion is entering of breast cancer cells in to the lymph or vascular/blood channels. | Baseline up to 30 months |
| Percentage of Participants With Different Phenotypes of Breast Cancer Based on ER Status | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. | Baseline up to 30 months |
| Percentage of Participants With Different Phenotypes of Breast Cancer Based on PR Status | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. | Baseline up to 30 months |
| Percentage of Participants With Different Phenotypes of Breast Cancer Based on HER2 Status | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. | Baseline up to 30 months |
| Percentage of Participants With Breast Cancer Phenotypes Among Different Hispanic Countries | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. | Baseline up to 30 months |
| Lima |
| Lima 13 |
| Peru |
| Lima | Peru |
| Montevideo | 11600 | Uruguay |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG000 | Breast Cancer Participants | Breast tissue samples from female participants with a breast cancer diagnosis that underwent an anatomopathological examination of surgical specimens and/or core needle biopsies were considered for analysis in this study. |
|
|
| Primary | Percentage of Participants With Different Phenotypes of Breast Cancer | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were estrogen receptor (ER) + and/or progesterone receptor (PR) +, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. Histological grading was done by Nottingham Histologic Score system based on three factors, a) the amount of gland formation (differentiation), b) the nuclear features (pleomorphism) and c) the mitotic activity. Each of these features is scored from 1-3, and then each score is added to give a final total score ranging from 3-9. The final total score is used to determine the grade in the following way: i) Grade 1 tumors have a score of 3-5, ii) Grade 2 tumors have a score of 6-7, and iii) Grade 3 tumors have a score of 8-9. | Included all breast cancer tissue samples for which the phenotype could be identified. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
| Primary | Percentage of Participants With Histological Sub-types of Breast Cancer | Histological subtypes of breast cancer included ductal carcinoma, lobular carcinoma, mucinous carcinoma, mixed carcinoma, metaplastic carcinoma, and others. | Included breast cancer tissue samples from all participants who were willing to participate in the study. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
| Primary | Percentage of Participants With ER Status (Positive or Negative) Across Different Age Groups | Participants were categorized in to following age groups: a) less than (<) 40 years, b) 40-49 years, c) 50-59 years, d) 60-69 years, e) greater than or equal to (≥) 70 years. | Included breast cancer tissue samples from all participants who were willing to participate in the study. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With ER Status (Positive or Negative) Based on Nuclear Grades | Nuclear pleomorphism was observed and graded accordingly. Grade 1: Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size; Grade 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape; Grade 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms. | Included breast cancer tissue samples from all participants who were willing to participate in the study. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With ER Status (Positive or Negative) Based on Lymphovascular Invasion | Lymphovascular invasion is entering of breast cancer cells in to the lymph or vascular/blood channels. | Included breast cancer tissue samples of all participants who were evaluable for this outcome measure. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With PR Status (Positive or Negative) Across Different Age Groups | Participants were categorized in to following age groups: a) <40 years, b) 40-49 years, c) 50-59 years, d) 60-69 years, e) ≥70 years. | Included breast cancer tissue samples from all participants who were willing to participate in the study. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With PR Status (Positive or Negative) Based on Nuclear Grades | Nuclear pleomorphism was observed and graded accordingly. Grade 1: Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size; Grade 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape; Grade 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms. | Included breast cancer tissue samples from all participants who were willing to participate in the study. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With PR Status (Positive or Negative) Based on Lymphovascular Invasion | Lymphovascular invasion is entering of breast cancer cells in to the lymph or vascular/blood channels. | Included breast cancer tissue samples of all participants who were evaluable for this outcome measure. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With HER2 Status (Positive or Negative) Across Different Age Groups | Participants were categorized in to following age groups: a) <40 years, b) 40-49 years, c) 50-59 years, d) 60-69 years, e) ≥70 years. | Included breast cancer tissue samples of all participants who were evaluable for this outcome measure. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With HER2 Status (Positive or Negative) Based on Nuclear Grades | Nuclear pleomorphism was observed and graded accordingly. Grade 1: Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size; Grade 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape; Grade 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms. | Included breast cancer tissue samples of all participants who were evaluable for this outcome measure. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With HER2 Status (Positive or Negative) Based on Lymphovascular Invasion | Lymphovascular invasion is entering of breast cancer cells in to the lymph or blood/vascular channels. | Included breast cancer tissue samples of all participants who were evaluable for this outcome measure. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With Different Phenotypes of Breast Cancer Across Different Age Groups | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. Participants were categorized in to following age groups: a) <40 years, b) 40-49 years, c) 50-59 years, d) 60-69 years, e) ≥70 years. | Included all breast cancer tissue samples for which the phenotype was identified. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With Different Phenotypes of Breast Cancer Based on Nuclear Grades | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. Nuclear pleomorphism was observed and graded accordingly. Grade 1: Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size; Grade 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape; Grade 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms. | Included all breast cancer tissue samples for which the phenotype was identified. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With Different Phenotypes of Breast Cancer Based on Lymphovascular Invasion | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. Lymphovascular invasion is entering of breast cancer cells in to the lymph or vascular/blood channels. | Included breast cancer tissue samples of all participants who were evaluable for this outcome measure. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With Different Phenotypes of Breast Cancer Based on ER Status | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. | Included all breast cancer tissue samples for which the phenotype was identified. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With Different Phenotypes of Breast Cancer Based on PR Status | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. | Included all breast cancer tissue samples for which the phenotype was identified. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With Different Phenotypes of Breast Cancer Based on HER2 Status | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. | Included all breast cancer tissue samples for which the phenotype was identified. | Posted | Number | percentage of participants | Baseline up to 30 months | Tissue samples | Tissue samples |
|
|
|
|
| Primary | Percentage of Participants With Breast Cancer Phenotypes Among Different Hispanic Countries | Breast cancer phenotypes were classified in to a) Luminal A: tissue samples that were ER+ and/or PR+, HER2-, and either histologic grade 1 or 2; b) Luminal B: tissue samples that were ER+ and/or PR+ and HER2+ or ER+ and/or PR+ and HER2- and histologic grade 3; c) HER2 enriched: tissue samples that were ER-, PR-, and HER2+; d) Triple negative: tissue samples that were negative for ER, PR, and HER2. | Included all breast cancer tissue samples for which the phenotype was identified. | Posted | Number | percentage of participants | Baseline up to 30 months | Number of Tissue samples | Number of Tissue samples |
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
| D017437 |
| Skin and Connective Tissue Diseases |
| Title | Measurements |
|---|---|
|
| Triple Negative |
|
| Title | Measurements |
|---|---|
|
| Mixed carcinoma |
|
| Metaplastic carcinoma |
|
| Others |
|
| 50-59 years |
|
| 60-69 years |
|
| ≥70 years |
|
| Nuclear grade 3 |
|
| 50-59 years |
|
| 60-69 years |
|
| ≥70 years |
|
| Nuclear grade 3 |
|
| 50-59 years |
|
| 60-69 years |
|
| ≥70 years |
|
| Nuclear grade 3 |
|
| Tissue samples |
|
| 40-49 years |
|
| 50-59 years |
|
| 60-69 years |
|
| ≥70 years |
|
| Tissue samples |
|
| Nuclear grade 2 |
|
| Nuclear grade 3 |
|
| Tissue samples |
|
| Absent |
|
| Tissue samples |
|
| ER Status: Negative |
|
| Tissue samples |
|
| PR Status: Negative |
|
| Tissue samples |
|
| HER2 Status: Negative |
|
| Number of Tissue samples |
|